Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:17:58.150Z.
Calculation as of: 2026-10-06T21:17:58.150Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6423558485129ce458f63e69d797580679928a9eb272818a894d3cfd838ee462
PEG RATIO
N/A
PharmaCyte Biotech, Inc.
Market Cap
$4.53M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.53M | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.69M | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
